Evidence mapPaperPMID 38706366Full record

ReviewCurrent diabetes reviews2025

Analytical and Bioanalytical Methods for the Determination of Dipeptidyl Peptidase-4 Inhibitors in Various Matrices: A Comprehensive Review.

Sakshi Hadawale, Sanjay Sharma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sakshi HadawaleDepartment of Quality Assurance, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Deemed to be University, Vile Parle West, Mumbai, Maharashtra, 400056, India.ORCID 0000-0001-7548-5370
Sanjay SharmaDepartment of Quality Assurance, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Deemed to be University, Vile Parle West, Mumbai, Maharashtra, 400056, India.ORCID 0000-0003-3662-4635

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDPP-4 inhibitors, or gliptins, are new oral antidiabetic drugs for type 2 diabetes. They help to regulate insulin and glucagon. These drugs have the advantage of a lower risk of hypoglycemia compared to some other diabetes medications and are typically prescribed when metformin and sulphonylureas have become less effective.

objectiveThis review analyses a range of analytical and bioanalytical methods for DPP-4 inhibitors, that use spectroscopic techniques, chromatographic, and hyphenated techniques for analysis. So far, no review comprising all DPP-4 inhibitors has been presented. The primary objective of this review is to present the analysts with various analytical and bioanalytical methods for the quantification and estimation of DPP-4 inhibitors in different matrices.

methodsTo improve understanding, a review was carried out by creating a database of pre-existing research from digital sources such as ScienceDirect, and PubMed. The methodology is shown in the flowchart of the literature selection process.

conclusionThe comprehensive assessment of methods for analysing DPP-4 inhibitors can be a valuable resource for researchers and healthcare practitioners. Hitherto, no review encompassing all DPP-4 inhibitors has been presented. Therefore, gaps in the data available on a particular subject, need to be required to collect data on a particular construct. The review suggests that chromatographic techniques were majorly used for analysis wherein solvents like acetonitrile, methanol, and buffer solutions were used as mobile phases that can deteriorate HPLC columns and equipment. So, scientists could investigate new methods for the assessment of DPP-4 inhibitors using more eco-friendly solvents.

Indexed as

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsHumansDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agentsdiabetes mellitusDPP-4 InhibitorsgliptinsHPLC.kidney diseasepharmacokinetics

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.